Calico Life Sciences, LLC, the Google-backed biotechnology company launched last year, has entered into a worldwide, exclusive license agreement with 2M Companies to develop P7C3 compounds, originally licensed from University of Texas (UT) Southwestern Medical Center, for the treatment of neurodegenerative diseases. These compounds have previously shown efficacy in mouse models of ALS, Parkinson’s disease and depression, and a paper published September 11 by researchers from UT Southwestern in the journal Cell reveals a new molecular target of these compounds, a key enzyme for energy metabolism and cell survival called NAMPT. Under the new license agreement between 2M and Calico, Calico will develop and commercialize compounds from the P7C3 program as well as fund research in several laboratories in the Dallas area. This announcement came one week after Calico and AbbVie announced establishment of a Bay Area research and development center in a deal potentially worth $1.5B.
Click here to read more.Share this: